---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-004933"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:24:02.303196+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma suspends at-the-market equity offering under Sales Agreement with ThinkEquity

## Summary
- Suspended prospectus supplement dated July 14, 2023; no sales of common stock until new filing.
- Sales Agreement with ThinkEquity LLC remains in full force and effect.
- No reason given for suspension; company may resume after filing new supplement.
- Suspension removes immediate dilution risk but pauses potential capital raising.

## SEC filing metadata
- accession: 0001493152-24-004933
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315224004933/0001493152-24-004933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315224004933/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-004933
- JSON: https://secwatch.observer/filing/0001493152-24-004933.json
- Plain text: https://secwatch.observer/filing/0001493152-24-004933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.